{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:57:12Z","timestamp":1793145432959,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clear evidence of overprescribing of psychotropic medicines to manage behaviours that challenges in people with intellectual disabilities\u00a0has led to national programmes within the U.K. such as NHS England\u2019s STOMP to address this. The focus of the intervention in our review was deprescribing of psychotropic medicines in children and adults with intellectual disabilities. Mental health symptomatology and quality of life were main outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We reviewed the evidence using databases Medline, Embase, PsycINFO, Web of Science, CINAHL and Open Grey with an initial cut-off date of 22nd August 2020 and an update on 14th March 2022. The first reviewer (DA) extracted data using a bespoke form and appraised study quality using CASP and Murad tools. The second reviewer (CS) independently assessed a random 20% of papers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Database searching identified 8675 records with 54 studies included in the final analysis.<\/jats:p>\n                <jats:p>The narrative synthesis suggests that psychotropic medicines can sometimes be deprescribed. Positive and negative consequences were reported. Positive effects on behaviour, mental and physical health were associated with an interdisciplinary model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first systematic review of the effects of deprescribing psychotropic medicines in people with intellectual disabilities which is not limited to antipsychotics. Main risks of bias were underpowered studies, poor recruitment processes, not accounting for other concurrent interventions and short follow up periods. Further research is needed to understand how to address the negative effects of deprescribing interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The protocol was registered with PROSPERO (registration number CRD42019158079)<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04479-w","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T11:03:07Z","timestamp":1680001387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Deprescribing psychotropic medicines for behaviours that challenge in people with intellectual disabilities: a systematic review"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-9540","authenticated-orcid":false,"given":"Danielle","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0495-8270","authenticated-orcid":false,"given":"Richard P.","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4152-9704","authenticated-orcid":false,"given":"Ian","family":"Maidment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-1825","authenticated-orcid":false,"given":"Peter E.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"4479_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association D and Association AP. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"4479_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0891-4222(00)00061-5","volume":"22","author":"E Emerson","year":"2001","unstructured":"Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Disabil. 2001;22:77\u201393. https:\/\/doi.org\/10.1016\/s0891-4222(00)00061-5.","journal-title":"Res Dev Disabil"},{"key":"4479_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ridd.2005.06.001","volume":"27","author":"B Holden","year":"2006","unstructured":"Holden B, Gitlesen JP. A total population study of challenging behaviour in the county of Hedmark, Norway: prevalence, and risk markers. Res Dev Disabil. 2006;27:456\u201365. https:\/\/doi.org\/10.1016\/j.ridd.2005.06.001.","journal-title":"Res Dev Disabil"},{"key":"4479_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/bjc.12118","volume":"56","author":"DL Bowring","year":"2017","unstructured":"Bowring DL, Totsika V, Hastings RP, et al. Challenging behaviours in adults with an intellectual disability: a total population study and exploration of risk indices. Br J Clin Psychol. 2017;56:16\u201332. https:\/\/doi.org\/10.1111\/bjc.12118.","journal-title":"Br J Clin Psychol"},{"key":"4479_CR5","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511543739","volume-title":"Challenging behaviour: analysis and intervention in people with severe intellectual disabilities","author":"E Emerson","year":"2001","unstructured":"Emerson E. Challenging behaviour: analysis and intervention in people with severe intellectual disabilities. 2nd ed. Cambridge: Cambridge University Press; 2001.","edition":"2"},{"key":"4479_CR6","volume-title":"Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges [CG11]","year":"2015","unstructured":"Excellence NIfHaC, editor. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges [CG11]. Excellence NIfHaC, (ed.); 2015."},{"key":"4479_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/s0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(17)32802-7.","journal-title":"Lancet"},{"key":"4479_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34:3\u201378.","journal-title":"J Psychopharmacol"},{"key":"4479_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/jir.12359","volume":"61","author":"DL Bowring","year":"2017","unstructured":"Bowring DL, Totsika V, Hastings RP, et al. Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study. J Intellect Disabil Res. 2017;61:604\u201317 Research Support, Non-U.S. Gov't.","journal-title":"J Intellect Disabil Res"},{"key":"4479_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1192\/bjp.bp.115.173971","volume":"209","author":"M O'Dwyer","year":"2016","unstructured":"O'Dwyer M, Maidment ID, Bennett K, et al. Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study. Br J Psychiatry. 2016;209:504\u201310.","journal-title":"Br J Psychiatry"},{"key":"4479_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1192\/bja.2018.45","volume":"25","author":"DC Owens","year":"2019","unstructured":"Owens DC. Tardive dyskinesia update: the syndrome. BJPsych Advances. 2019;25:57\u201369.","journal-title":"BJPsych Advances"},{"key":"4479_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881116645254","volume":"30","author":"SJ Cooper","year":"2016","unstructured":"Cooper SJ, Reynolds GP, Wec-a, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30:717\u201348.","journal-title":"J Psychopharmacol"},{"key":"4479_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1108\/amhid-02-2018-0004","volume":"13","author":"D Branford","year":"2019","unstructured":"Branford D, Gerrard D, Saleem N, et al. Stopping over-medication of people with intellectual disability, autism or both (STOMP) in England part 1-history and background of STOMP. Adv Ment Health Intellect Disabil. 2019;13:31\u201340. https:\/\/doi.org\/10.1108\/amhid-02-2018-0004.","journal-title":"Adv Ment Health Intellect Disabil"},{"key":"4479_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1108\/amhid-02-2018-0005","volume":"13","author":"D Branford","year":"2019","unstructured":"Branford D, Gerrard D, Saleem N, et al. Stopping over-medication of people with an intellectual disability, autism or both (STOMP) in England part 2-the story so far. Adv Ment Health Intellect Disabil. 2019;13:41\u201351. https:\/\/doi.org\/10.1108\/amhid-02-2018-0005.","journal-title":"Adv Ment Health Intellect Disabil"},{"key":"4479_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S2215-0366(16)30191-2","volume":"4","author":"R Sheehan","year":"2017","unstructured":"Sheehan R, Hassiotis A. Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. Lancet Psychiatry. 2017;4:238\u201356 Systematic Review.","journal-title":"Lancet Psychiatry"},{"key":"4479_CR16","volume-title":"Critical appraisal skills Programme (CASP)","author":"(CASP). CASP","year":"2015","unstructured":"(CASP). CASP. Critical appraisal skills Programme (CASP). https:\/\/casp-uk.net\/casp-tools-checklists\/; 2015."},{"key":"4479_CR17","doi-asserted-by":"crossref","unstructured":"Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med. 2018:23.","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"4479_CR18","unstructured":"Popay JRH, Sowden A, Petticrew M, Arai L, Rodgers M, Britten N, et al. Guidance on the conduct of narrative synthesis in systematic reviews. ESRC Methods Programme. 2006."},{"key":"4479_CR19","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"4479_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","volume":"162","author":"Risperidone Treatment of Autistic Disorder","year":"2005","unstructured":"Risperidone Treatment of Autistic Disorder. Longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162:1361\u20139.","journal-title":"Am J Psychiatry"},{"key":"4479_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.176.1.42","volume":"176","author":"Z Ahmed","year":"2000","unstructured":"Ahmed Z, Fraser W, Kerr MP, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry. 2000;176:42\u20136 Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't.","journal-title":"Br J Psychiatry"},{"key":"4479_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1365-2788.2002.00416.x","volume":"46","author":"C Smith","year":"2002","unstructured":"Smith C, Felce D, Ahmed Z, et al. Sedation effects on responsiveness: evaluating the reduction of antipsychotic medication in people with intellectual disability using a conditional probability approach. J Intellect Disabil Res. 2002;46:464\u201371 Evaluation Study Research Support, Non-U.S. Gov't.","journal-title":"J Intellect Disabil Res"},{"key":"4479_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2788.2012.01631.x","volume":"58","author":"G de Kuijper","year":"2014","unstructured":"de Kuijper G, Evenhuis H, Minderaa RB, et al. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J Intellect Disabil Res. 2014;58:71\u201383 Clinical Trial Multicenter Study.","journal-title":"J Intellect Disabil Res"},{"key":"4479_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/JCP.0b013e3182905d6a","volume":"33","author":"G de Kuijper","year":"2013","unstructured":"de Kuijper G, Mulder H, Evenhuis H, et al. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. J Clin Psychopharmacol. 2013;33:520\u20134.","journal-title":"J Clin Psychopharmacol."},{"key":"4479_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/JCP.0b013e3182a60848","volume":"34","author":"GM de Kuijper","year":"2014","unstructured":"de Kuijper GM, Mulder H, Evenhuis H, et al. Effects of discontinuation of long-term used antipsychotics on prolactin and bone turnover markers in patients with intellectual disability. J Clin Psychopharmacol. 2014;34:157\u20139.","journal-title":"J Clin Psychopharmacol."},{"key":"4479_CR26","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/jcph.1271","volume":"58","author":"GM de Kuijper","year":"2018","unstructured":"de Kuijper GM, Hoekstra PJ. An open-label discontinuation trial of long-term, off-label antipsychotic medication in people with intellectual disability: Determinants of success and failure. J Clin Pharmacol. 2018;58:1418\u201326.","journal-title":"J Clin Pharmacol."},{"key":"4479_CR27","doi-asserted-by":"crossref","unstructured":"de Kuijper GM, Mulder H, Evenhuis H, et al. Effects of discontinuation of long-term used antipsychotics on prolactin and bone turnover markers in patients with intellectual disability. J Clin Psychopharmacol. 2014;34:157\u20139 Letter Multicenter Study Research Support, Non-U.S. Gov't.","DOI":"10.1097\/JCP.0b013e3182a60848"},{"key":"4479_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1192\/bjp.bp.105.016535","volume":"190","author":"F Haessler","year":"2007","unstructured":"Haessler F, Glaser T, Beneke M, et al. Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study. Br J Psychiatry. 2007;190:447\u20138 Multicenter Study Randomized Controlled Trial.","journal-title":"Br J Psychiatry"},{"key":"4479_CR29","first-page":"339343","volume":"44","author":"F Hassler","year":"2011","unstructured":"Hassler F, Glaser T, Reis O. Effects of zuclopenthixol on aggressive disruptive behavior in adults with mental retardation--a 2-year follow-up on a withdrawal study. Pharmacopsychiatry. 2011;44:339343 Multicenter Study.","journal-title":"Pharmacopsychiatry"},{"key":"4479_CR30","first-page":"243","volume":"87","author":"GT Heistad","year":"1982","unstructured":"Heistad GT, Zimmermann RL, Doebler MI. Long-term usefulness of thioridazine for institutionalized mentally retarded patients. Am J Ment Defic. 1982;87:243\u201351 Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.","journal-title":"Am J Ment Defic"},{"key":"4479_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21470","volume":"21","author":"R McNamara","year":"2017","unstructured":"McNamara R, Randell E, Gillespie D, et al. A pilot randomised controlled trial of community-led ANtipsychotic drug REduction for adults with learning disabilities. Health Technol Assessm (Winchester, England). 2017;21:1\u201392 Randomized Controlled Trial.","journal-title":"Health Technol Assessm (Winchester, England)"},{"key":"4479_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/jir.12584","volume":"63","author":"L Ramerman","year":"2019","unstructured":"Ramerman L, de Kuijper G, Scheers T, et al. Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study. J Intellect Disabil Res. 2019;63:418\u201328. https:\/\/doi.org\/10.1111\/jir.12584.","journal-title":"J Intellect Disabil Res"},{"key":"4479_CR33","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/jcph.1271","volume":"58","author":"GM de Kuijper","year":"2018","unstructured":"de Kuijper GM, Hoekstra PJ. An open-label discontinuation trial of long-term, off-label antipsychotic medication in people with intellectual disability: determinants of success and failure. J Clin Pharmacol. 2018;58:1418\u201326 Clinical Trial Research Support, Non-U.S. Gov't.","journal-title":"J Clin Pharmacol"},{"key":"4479_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jcph.1311","volume":"59","author":"L Ramerman","year":"2019","unstructured":"Ramerman L, Hoekstra PJ, Kuijper G. Changes in health-related quality of life in people with intellectual disabilities who discontinue long-term used antipsychotic drugs for challenging behaviors. J Clin Pharmacol. 2019;59:280\u20137. https:\/\/doi.org\/10.1002\/jcph.1311.","journal-title":"J Clin Pharmacol"},{"key":"4479_CR35","first-page":"187","volume":"29","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. J Ment Defic Res. 1985;29:187\u201395.","journal-title":"J Ment Defic Res"},{"key":"4479_CR36","first-page":"105","volume":"5","author":"M Carpenter","year":"1990","unstructured":"Carpenter M, Cowart CA, McCallum RS, et al. Effects of antipsychotic medication on discrimination learning for institutionalized adults who have mental retardation. Behavior Resident Treatm. 1990;5:105\u201320.","journal-title":"Behavior Resident Treatm"},{"key":"4479_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1108\/AMHID-12-2018-0051","volume":"13","author":"D Gerrard","year":"2019","unstructured":"Gerrard D, Rhodes J, Lee R, et al. Using positive behavioural support (PBS) for STOMP medication challenge. Adv Ment Health Intellect Disabil. 2019;13:102\u201312. https:\/\/doi.org\/10.1108\/AMHID-12-2018-0051.","journal-title":"Adv Ment Health Intellect Disabil"},{"key":"4479_CR38","volume-title":"Delivering STOMP in a community learning disability treatment team hospital pharmacy Europe","author":"D Gerrard","year":"2020","unstructured":"Gerrard D. Delivering STOMP in a community learning disability treatment team hospital pharmacy Europe; 2020."},{"key":"4479_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1037\/1064-1297.4.2.218","volume":"4","author":"JM Swanson","year":"1996","unstructured":"Swanson JM, Christian DL, Wigal T, et al. Tardive dyskinesia in a developmentally disabled population: manifestation during the initial stage of a minimal effective dose program. Exp Clin Psychopharmacol. 1996;4:218\u201323.","journal-title":"Exp Clin Psychopharmacol"},{"key":"4479_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF01046598","volume":"5","author":"T Wigal","year":"1993","unstructured":"Wigal T, Christian DL, Wigal SB, et al. Classification of types of tardive dyskinesia in a developmentally disabled population at a public residential facility. J Dev Phys Disabil. 1993;5:55\u201369.","journal-title":"J Dev Phys Disabil"},{"key":"4479_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF02579354","volume":"6","author":"T Wigal","year":"1994","unstructured":"Wigal T, Swanson JM, Christian DL, et al. Admissions to a public residential facility for individuals with developmental disabilities: change in neuroleptic drug use and tardive dykinesia. J Dev Phys Disabil. 1994;6:115\u201324.","journal-title":"J Dev Phys Disabil"},{"key":"4479_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/cap.2000.10.79","volume":"10","author":"A Zuddas","year":"2000","unstructured":"Zuddas A, Di Martino A, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adoles Psychopharmacol. 2000;10:79\u201390 Clinical Trial.","journal-title":"J Child Adoles Psychopharmacol"},{"key":"4479_CR43","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/00004714-200306000-00014","volume":"23","author":"NC Brahm","year":"2003","unstructured":"Brahm NC, Buswell A, Christensen D, et al. Assessment of QTc prolongation following thioridazine withdrawal in a developmentally disabled population. J Clin Psychopharmacol. 2003;23:314\u20135 Letter.","journal-title":"J Clin Psychopharmacol"},{"key":"4479_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2788.1996.tb00641.x","volume":"40","author":"D Branford","year":"1996","unstructured":"Branford D. A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. J Intellect Disabil Res. 1996;40:358\u201368.","journal-title":"J Intellect Disabil Res"},{"key":"4479_CR45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/jar.12528","volume":"32","author":"GM de Kuijper","year":"2019","unstructured":"de Kuijper GM, Hoekstra PJ. An open label discontinuation trial of long-term used off-label antipsychotic drugs in people with intellectual disability: the influence of staff-related factors. J Appl Res Intellect Disabil. 2019;32:313\u201322 Clinical Trial.","journal-title":"J Appl Res Intellect Disabil"},{"key":"4479_CR46","first-page":"604","volume":"34","author":"GL Ellenor","year":"1977","unstructured":"Ellenor GL, Frisk PA. Pharmacist impact on drug use in an institution for the mentally retarded. Am J Hosp Pharm. 1977;34:604\u20138 Research Support, U.S. Gov't, Non-P.H.S.","journal-title":"Am J Hosp Pharm"},{"key":"4479_CR47","first-page":"103","volume":"17","author":"DG Ferguson","year":"1982","unstructured":"Ferguson DG, Cullari S, Davidson NA, et al. Effects of data-based interdisciplinary medication reviews on the prevalence and pattern of neuroleptic drug use with institutionalized mentally retarded persons. Educ Train Menta Retard. 1982;17:103\u20138.","journal-title":"Educ Train Menta Retard"},{"key":"4479_CR48","first-page":"771","volume":"31","author":"LT Fielding","year":"1980","unstructured":"Fielding LT, Murphy RJ, Reagan MW, et al. An assessment program to reduce drug use with the mentally retarded. Hosp Community Psychiatry. 1980;31:771\u20133 Comparative Study.","journal-title":"Hosp Community Psychiatry"},{"key":"4479_CR49","first-page":"41","volume":"28","author":"NE Findholt","year":"1990","unstructured":"Findholt NE, Emmett CG. Impact of interdisciplinary team review on psychotropic drug use with persons who have mental retardation. Ment Retard. 1990;28:41\u20136.","journal-title":"Ment Retard"},{"key":"4479_CR50","first-page":"78","volume":"5","author":"K Howerton","year":"2002","unstructured":"Howerton K, Fernandez G, Touchette PE, et al. Psychotropic medications in community based individuals with developmental disabilities: observations of an interdisciplinary team. Mental Health Aspects Dev Disabil. 2002;5:78\u201386.","journal-title":"Mental Health Aspects Dev Disabil"},{"key":"4479_CR51","first-page":"70","volume":"20","author":"F Inoue","year":"1982","unstructured":"Inoue F. A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons. Ment Retard. 1982;20:70\u20134.","journal-title":"Ment Retard"},{"key":"4479_CR52","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4088\/JCP.v67n0815","volume":"67","author":"DS Janowsky","year":"2006","unstructured":"Janowsky DS, Barnhill LJ, Khalid AS, et al. Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later. J Clin Psychiatry. 2006;67:1272\u20137 Comparative Study.","journal-title":"J Clin Psychiatry"},{"key":"4479_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/JCP.0b013e31817e63b9","volume":"28","author":"DS Janowsky","year":"2008","unstructured":"Janowsky DS, Barnhill LJ, Khalid AS, et al. Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. J Clin Psychopharmacol. 2008;28:401\u20135 Multicenter Study.","journal-title":"J Clin Psychopharmacol"},{"key":"4479_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/07263869500035431","volume":"20","author":"R Jauernig","year":"1995","unstructured":"Jauernig R, Hudson A. Evaluation of an interdisciplinary review committee managing the use of psychotropic medication with people with intellectual disabilities. Austr New Zealand J Dev Disabil. 1995;20:51\u201361.","journal-title":"Austr New Zealand J Dev Disabil"},{"key":"4479_CR55","doi-asserted-by":"crossref","unstructured":"LaMendola W, Zabaria ES, Carver M. Reducing psychotropic drug use in an institution for the retarded. Hosp Community Psychiatry. 1980:31.","DOI":"10.1176\/ps.31.4.271"},{"key":"4479_CR56","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/000992280404300504","volume":"43","author":"RL Lindsay","year":"2004","unstructured":"Lindsay RL, Leone S, Aman MG. Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr. 2004;43:437\u201344.","journal-title":"Clin Pediatr"},{"key":"4479_CR57","first-page":"165","volume":"98","author":"DJ Luchins","year":"1993","unstructured":"Luchins DJ, Dojka DM, Hanrahan P. Factors associated with reduction in antipsychotic medication dosage in adults with mental retardation. Am J Ment Retard. 1993;98:165\u201372 Comparative Study.","journal-title":"Am J Ment Retard"},{"key":"4479_CR58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1901\/jaba.1979.12-159","volume":"12","author":"D Marholin 2nd","year":"1979","unstructured":"Marholin D 2nd, Touchette PE, Stewart RM. Withdrawal of chronic chlorpromazine medication: an experimental analysis. J Appl Behav Anal. 1979;12:159\u201371 Clinical Trial Controlled Clinical Trial.","journal-title":"J Appl Behav Anal"},{"key":"4479_CR59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1192\/pb.27.3.87","volume":"27","author":"T Matthews","year":"2003","unstructured":"Matthews T, Weston SN. Experience of thioridazine use before and after the committee on safety of medicines warning. Psychiatr Bull. 2003;27:87\u20139.","journal-title":"Psychiatr Bull"},{"key":"4479_CR60","first-page":"827","volume":"20","author":"AW Marcoux","year":"1985","unstructured":"Marcoux AW. Implementation of a psychotropic drug review service in a mental retardation facility. Hosp Pharm. 1985;20:827\u201331.","journal-title":"Hosp Pharm"},{"key":"4479_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/10401239509149620","volume":"7","author":"P May","year":"1995","unstructured":"May P, London EB, Zimmerman T, et al. A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry. 1995;7:155\u201360.","journal-title":"Ann Clin Psychiatry"},{"key":"4479_CR62","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1352\/0895-8017(2000)105<0260:DOLDAW>2.0.CO;2","volume":"105","author":"KM Newell","year":"2000","unstructured":"Newell KM, Bodfish JW, Mahorney SL, et al. Dynamics of lip dyskinesia associated with neuroleptic withdrawal. Am J Ment Retard. 2000;105:260\u20138 Research Support, U.S. Gov't, P.H.S.","journal-title":"Am J Ment Retard"},{"key":"4479_CR63","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1037\/1064-1297.9.3.262","volume":"9","author":"KM Newell","year":"2001","unstructured":"Newell KM, Wszola B, Sprague RL, et al. The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal. Exp Clin Psychopharmacol. 2001;9:262\u20138 Clinical Trial Research Support, U.S. Gov't, P.H.S.","journal-title":"Exp Clin Psychopharmacol"},{"key":"4479_CR64","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1352\/0895-8017(2002)107<0270:OODACI>2.0.CO;2","volume":"107","author":"KM Newell","year":"2002","unstructured":"Newell KM, Ko YG, Sprague RL, et al. Onset of dyskinesia and changes in postural task performance during the course of neuroleptic withdrawal. Am J Ment Retard. 2002;107:270\u20137 Research Support, U.S. Gov't, P.H.S.","journal-title":"Am J Ment Retard"},{"key":"4479_CR65","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/jar.12635","volume":"32","author":"R Shankar","year":"2019","unstructured":"Shankar R, Wilcock M, Deb S, et al. A structured programme to withdraw antipsychotics among adults with intellectual disabilities: the Cornwall experience. J Appl Res Intellect Disabil. 2019;32:1389\u2013400.","journal-title":"J Appl Res Intellect Disabil"},{"key":"4479_CR66","first-page":"1100","volume":"44","author":"S Spreat","year":"1993","unstructured":"Spreat S, Serafin C, Behar D, et al. Tranquilizer reduction trials in a residential program for persons with mental retardation. Hosp Community Psychiatry. 1993;44:1100\u20132.","journal-title":"Hosp Community Psychiatry"},{"key":"4479_CR67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1017\/S0790966700008417","volume":"21","author":"C Stevenson","year":"2004","unstructured":"Stevenson C, Rajan L, Reid G, et al. Withdrawal of antipsychotic drugs from adults with intellectual disabilities. Ir J Psychol Med. 2004;21:85\u201390.","journal-title":"Ir J Psychol Med"},{"key":"4479_CR68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/ejhpharm-2016-001051","volume":"24","author":"D Adams","year":"2017","unstructured":"Adams D, Sawhney I. Deprescribing of psychotropic medication in a 30-year-old man with learning disability. Eur J Hosp Pharm. 2017;24:63\u20134.","journal-title":"Eur J Hosp Pharm"},{"key":"4479_CR69","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/0004867413499943","volume":"48","author":"T Bastiampillai","year":"2014","unstructured":"Bastiampillai T, Fantasia R, Nelson A. De novo treatment-resistant psychosis following thioridazine withdrawal. Aust N Z J Psychiatry. 2014;48:585\u20136.","journal-title":"Aust N Z J Psychiatry"},{"key":"4479_CR70","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4088\/PCC.08l00722","volume":"11","author":"NC Brahm","year":"2009","unstructured":"Brahm NC, Fast GA. Increased sexual aggression following ziprasidone discontinuation in an intellectually disabled adult man. Prim Care Companion J Clin Psych. 2009;11:361.","journal-title":"Prim Care Companion J Clin Psych"},{"key":"4479_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00004583-199803000-00005","volume":"37","author":"DF Connor","year":"1998","unstructured":"Connor DF. Stimulants and neuroleptic withdrawal dyskinesia. J Am Acad Child Adolesc Psychiatry. 1998;37:247\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"4479_CR72","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/088307389000500406","volume":"5","author":"JE Dillon","year":"1990","unstructured":"Dillon JE. Self-injurious behavior associated with clonidine withdrawal in a child with Tourette's disorder. J Child Neurol. 1990;5:308\u201310.","journal-title":"J Child Neurol"},{"key":"4479_CR73","doi-asserted-by":"crossref","unstructured":"Faisal M, Pradeep V, O'Hanrahan S. Case of paediatric catatonia precipitated by antipsychotic withdrawal in a child with autism spectrum disorder. BMJ Case Rep. 2021;14(4):e240785.","DOI":"10.1136\/bcr-2020-240785"},{"key":"4479_CR74","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/070674379003500710","volume":"35","author":"N Ghaziuddin","year":"1990","unstructured":"Ghaziuddin N, Ghaziuddin M. Mania-like reaction induced by benzodiazepine withdrawal in a patient with mental retardation. Can J Psychiatr Rev Can Psychiatr. 1990;35:612\u20133 Case Reports.","journal-title":"Can J Psychiatr Rev Can Psychiatr"},{"key":"4479_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1108\/tldr-06-2018-0018","volume":"24","author":"RM Lee","year":"2019","unstructured":"Lee RM, Rhodes JA, Gerrard D. Positive Behavioural support as an alternative to medication. Tizard Learn Disabil Rev. 2019;24:1\u20138. https:\/\/doi.org\/10.1108\/tldr-06-2018-0018.","journal-title":"Tizard Learn Disabil Rev"},{"key":"4479_CR76","first-page":"141","volume":"28","author":"JD McLennan","year":"2019","unstructured":"McLennan JD. Deprescribing in a youth with an intellectual disability, autism, behavioural problems, and medication-related obesity: a case study. J Can Acad Child Adolesc Psychiatry. 2019;28:141\u20136.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"4479_CR77","volume-title":"Delivering STOMP in a community learning disability treatment team hospital pharmacy Europe","author":"D Gerrard","year":"2019","unstructured":"Gerrard D. Delivering STOMP in a community learning disability treatment team hospital pharmacy Europe; 2019."},{"key":"4479_CR78","first-page":"14","volume":"3","author":"NJ Gore","year":"2013","unstructured":"Gore NJ, McGill P, Toogood S, et al. Definition and scope for positive behavioural support. Int J Positive Behavioural Support. 2013;3:14\u201323.","journal-title":"Int J Positive Behavioural Support"},{"key":"4479_CR79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1055\/s-0028-1082072","volume":"41","author":"F Hassler","year":"2008","unstructured":"Hassler F, Glaser T, Pap AF, et al. A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses. Pharmacopsychiatry. 2008;41:232\u20139 Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't.","journal-title":"Pharmacopsychiatry"},{"key":"4479_CR80","unstructured":"Organisation WH. Adolescent health. https:\/\/www.who.int\/health-topics\/adolescent-health. Accessed 14 Mar 2022."},{"key":"4479_CR81","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/JCP.0b013e3182905d6a","volume":"33","author":"G de Kuijper","year":"2013","unstructured":"de Kuijper G, Mulder H, Evenhuis H, et al. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. J Clin Psychopharmacol. 2013;33:520\u20134 Clinical Trial Multicenter Study Research Support, Non-U.S. Gov't.","journal-title":"J Clin Psychopharmacol"},{"key":"4479_CR82","first-page":"64","volume":"10","author":"MG Valdovinos","year":"2007","unstructured":"Valdovinos MG, Ellringer NP, Alexander ML. Changes in the rate of problem behavior associated with the discontinuation of the antipsychotic medication quetiapine. Mental Health Aspects Dev Disabil. 2007;10:64\u20137.","journal-title":"Mental Health Aspects Dev Disabil"},{"key":"4479_CR83","doi-asserted-by":"publisher","DOI":"10.5042\/tldr.2011.0008","volume-title":"Health inequalities and people with learning disabilities in the UK","author":"E Emerson","year":"2011","unstructured":"Emerson E, Baines S, Allerton L, et al. Health inequalities and people with learning disabilities in the UK; 2011."},{"key":"4479_CR84","doi-asserted-by":"publisher","unstructured":"Challenging behaviour: a unified approach. Psychiatr Bull. 2007;31:400\u20130. https:\/\/doi.org\/10.1192\/pb.31.10.400.","DOI":"10.1192\/pb.31.10.400"},{"key":"4479_CR85","doi-asserted-by":"publisher","first-page":"e017406","DOI":"10.1136\/bmjopen-2017-017406","volume":"7","author":"R Sheehan","year":"2017","unstructured":"Sheehan R, Horsfall L, Strydom A, et al. Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open. 2017;7:e017406. https:\/\/doi.org\/10.1136\/bmjopen-2017-017406.","journal-title":"BMJ Open"},{"key":"4479_CR86","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jir.12385","volume":"61","author":"GM de Kuijper","year":"2017","unstructured":"de Kuijper GM, Hoekstra PJ. Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability. J Intellect Disabil Res. 2017;61:899\u2013908. https:\/\/doi.org\/10.1111\/jir.12385.","journal-title":"J Intellect Disabil Res"},{"key":"4479_CR87","unstructured":"Adams D, Carr C, Marsden D, et al. An update on informed consent and the effect on the clinical practice of those working with people with a learning disability. Learn Disabil Pract. 2021;24."},{"key":"4479_CR88","volume-title":"Making shared decision-making a reality","author":"A Coulter","year":"2011","unstructured":"Coulter A, Collins A. Making shared decision-making a reality. London: King's Fund; 2011."},{"key":"4479_CR89","volume-title":"Polypharmacy and medicines optimisation","author":"MAT Duerden","year":"2013","unstructured":"Duerden MAT, Payne R. Polypharmacy and medicines optimisation: The King's Fund; 2013."},{"key":"4479_CR90","volume-title":"The learning disabilities mortality review (LeDeR) Programme: annual report 2019","author":"P Heslop","year":"2020","unstructured":"Heslop P, Calkin R, Byrne V. The learning disabilities mortality review (LeDeR) Programme: annual report 2019. University of Bristol, Norah Fry Centre for Disability Studies; 2020."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04479-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04479-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04479-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T12:06:59Z","timestamp":1680005219000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04479-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4479"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04479-w","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"22 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}